Skip to main content
Erschienen in: Annals of Surgical Oncology 2/2016

01.02.2016 | Gastrointestinal Oncology

Impact of the Surveillance Interval on the Survival of Patients Who Undergo Curative Surgery for Gastric Cancer

verfasst von: Chan Hyuk Park, MD, Jun Chul Park, MD, Hyunsoo Chung, MD, Sung Kwan Shin, MD, Sang Kil Lee, MD, PhD, Jae-Ho Cheong, MD, PhD, Woo Jin Hyung, MD, PhD, Yong Chan Lee, MD, PhD, Sung Hoon Noh, MD, PhD, Choong Bae Kim, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

For patients who undergo gastrectomy for gastric cancer, systematic follow-up evaluation to detect recurrent lesions is recommended, although the benefits of a surveillance program using short-term imaging studies have not been evaluated.

Methods

This study reviewed the clinical data of patients who underwent curative surgery for gastric cancer using a prospective database. Patients with recurrence were classified according to surveillance interval as follows: ≤3, 3–6, and 6–12 months.

Results

Of the 2785 patients who underwent curative surgery for gastric cancer, 376 (13.5 %) had intraabdominal recurrences, excluding the stomach. Multivariable analysis showed that a short surveillance interval did not increase the post-recurrence survival duration (with 6–12 months as the reference: ≤3 months: hazard ratio [HR] 0.954; 95 % confidence interval [CI] 0.689–1.323; 3–6 months: HR 0.994, 95 % CI 0.743–1.330). In addition, short surveillance intervals did not increase overall survival (with 6–12 months as the reference: ≤3 months: HR 0.969; 95 % CI 0.699–1.342; 3–6 months: HR 0.955; 95 % CI 0.711–1.285). In contrast to the surveillance interval, age, cancer stage, symptoms at recurrence, and recurrence time after gastrectomy were factors associated with both post-recurrence survival and overall survival.

Conclusions

Although the detection of recurrence before symptoms helped to prolong both post-recurrence survival and overall survival, shortening the surveillance interval to less than 6 months did not improve either the patient’s post-recurrence survival or overall survival. Hence, it is not recommended that asymptomatic patients undergo surveillance involving imaging studies more often than once a year.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
3.
Zurück zum Zitat Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16:1–27.PubMedPubMedCentralCrossRef Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16:1–27.PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Shimizu S, Tada M, Kawai K. Early gastric cancer: its surveillance and natural course. Endoscopy. 1995;27:27–31.PubMedCrossRef Shimizu S, Tada M, Kawai K. Early gastric cancer: its surveillance and natural course. Endoscopy. 1995;27:27–31.PubMedCrossRef
6.
Zurück zum Zitat Sougioultzis S, Syrios J, Xynos ID, et al. Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: a retrospective analysis. Eur J Surg Oncol. 2011;37:312–8.PubMedCrossRef Sougioultzis S, Syrios J, Xynos ID, et al. Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: a retrospective analysis. Eur J Surg Oncol. 2011;37:312–8.PubMedCrossRef
7.
Zurück zum Zitat Chen W, Wang F, Xu R. Platinum-based versus non-platinum-based chemotherapy as first-line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis. PLoS One. (2013);8:e68974-e.PubMedPubMedCentralCrossRef Chen W, Wang F, Xu R. Platinum-based versus non-platinum-based chemotherapy as first-line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis. PLoS One. (2013);8:e68974-e.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Park J, Ryu W, Kim J, et al. Prognostic factors for advanced gastric cancer: stage-stratified analysis of patients who underwent curative resection. Cancer Res Treat. 2006;38:13–8.PubMedPubMedCentralCrossRef Park J, Ryu W, Kim J, et al. Prognostic factors for advanced gastric cancer: stage-stratified analysis of patients who underwent curative resection. Cancer Res Treat. 2006;38:13–8.PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on cancer staging, proximal disease, and the “different disease” hypothesis. Cancer. 2000;88:921–32.PubMedCrossRef Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on cancer staging, proximal disease, and the “different disease” hypothesis. Cancer. 2000;88:921–32.PubMedCrossRef
10.
Zurück zum Zitat Choi YY, An JY, Cho I, et al. The assessment of the oncological safety margin of insufficient lymph node dissection in pT2 (pm) gastric cancer. Yonsei Med J. 2014;55:61–9.PubMedPubMedCentralCrossRef Choi YY, An JY, Cho I, et al. The assessment of the oncological safety margin of insufficient lymph node dissection in pT2 (pm) gastric cancer. Yonsei Med J. 2014;55:61–9.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Tan IT, So BY. Value of intensive follow-up of patients after curative surgery for gastric carcinoma. J Surg Oncol. 2007;96:503–6.PubMedCrossRef Tan IT, So BY. Value of intensive follow-up of patients after curative surgery for gastric carcinoma. J Surg Oncol. 2007;96:503–6.PubMedCrossRef
13.
Zurück zum Zitat D’Ugo D, ABiondi A, Tufo A, Baiocchi G, Persiani R. Surveillance after gastric resection. In: Strong VE, editor. Gastric cancer: principles and practice. Switzerland: Springer International Publishing; 2015. p. 255–70.CrossRef D’Ugo D, ABiondi A, Tufo A, Baiocchi G, Persiani R. Surveillance after gastric resection. In: Strong VE, editor. Gastric cancer: principles and practice. Switzerland: Springer International Publishing; 2015. p. 255–70.CrossRef
14.
Zurück zum Zitat Bennett J, Gonen M, D’Angelica M, Jaques DP, Brennan MF, Coit DG. Is detection of asymptomatic recurrence after curative resection associated with improved survival in patients with gastric cancer? J Am Coll Surg. 2005;201:503–10.PubMedCrossRef Bennett J, Gonen M, D’Angelica M, Jaques DP, Brennan MF, Coit DG. Is detection of asymptomatic recurrence after curative resection associated with improved survival in patients with gastric cancer? J Am Coll Surg. 2005;201:503–10.PubMedCrossRef
15.
Zurück zum Zitat Kodera Y, Ito S, Yamamura Y, et al. Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol. 2003;10:898–902.PubMedCrossRef Kodera Y, Ito S, Yamamura Y, et al. Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol. 2003;10:898–902.PubMedCrossRef
16.
Zurück zum Zitat Chiang C, Huang K, Fang W, et al. Factors associated with recurrence within 2 years after curative surgery for gastric adenocarcinoma. World J Surg. 2011;35:2472–8.PubMedCrossRef Chiang C, Huang K, Fang W, et al. Factors associated with recurrence within 2 years after curative surgery for gastric adenocarcinoma. World J Surg. 2011;35:2472–8.PubMedCrossRef
17.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef
18.
Zurück zum Zitat An JY, Heo G, Cheong J, Hyung WJ, Choi SH, Noh SH. Assessment of open versus laparoscopy-assisted gastrectomy in lymph node-positive early gastric cancer: a retrospective cohort analysis. J Surg Oncol. 2010;102:77–81.PubMedCrossRef An JY, Heo G, Cheong J, Hyung WJ, Choi SH, Noh SH. Assessment of open versus laparoscopy-assisted gastrectomy in lymph node-positive early gastric cancer: a retrospective cohort analysis. J Surg Oncol. 2010;102:77–81.PubMedCrossRef
19.
Zurück zum Zitat Greene FL. American Joint Committee on Cancer, AJCC cancer staging manual. New York: Springer; 2010. Greene FL. American Joint Committee on Cancer, AJCC cancer staging manual. New York: Springer; 2010.
20.
Zurück zum Zitat Li F, Zhang R, Liang H, Liu H, Quan J. The pattern and risk factors of recurrence of proximal gastric cancer after curative resection. J Surg Oncol. 2013;107:130–5.PubMedCrossRef Li F, Zhang R, Liang H, Liu H, Quan J. The pattern and risk factors of recurrence of proximal gastric cancer after curative resection. J Surg Oncol. 2013;107:130–5.PubMedCrossRef
21.
Zurück zum Zitat Kim H, Han S, Kim M, et al. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. J Clin Oncol. 2014;32:627–33.PubMedCrossRef Kim H, Han S, Kim M, et al. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. J Clin Oncol. 2014;32:627–33.PubMedCrossRef
22.
Zurück zum Zitat Shinohara T, Satoh S, Kanaya S, et al. Laparoscopic versus open D2 gastrectomy for advanced gastric cancer: a retrospective cohort study. Surg Endosc. 2013;27:286–94.PubMedCrossRef Shinohara T, Satoh S, Kanaya S, et al. Laparoscopic versus open D2 gastrectomy for advanced gastric cancer: a retrospective cohort study. Surg Endosc. 2013;27:286–94.PubMedCrossRef
23.
Zurück zum Zitat Fang C, Hua J, Li J, et al. Comparison of long-term results between laparoscopy-assisted gastrectomy and open gastrectomy with D2 lymphadenectomy for advanced gastric cancer. Am J Surg. 2014;208:391–6.PubMedCrossRef Fang C, Hua J, Li J, et al. Comparison of long-term results between laparoscopy-assisted gastrectomy and open gastrectomy with D2 lymphadenectomy for advanced gastric cancer. Am J Surg. 2014;208:391–6.PubMedCrossRef
24.
Zurück zum Zitat Sato H, Shimada M, Kurita N, et al. Comparison of long-term prognosis of laparoscopy-assisted gastrectomy and conventional open gastrectomy with special reference to D2 lymph node dissection. Surg Endosc. 2012;26:2240–6.PubMedCrossRef Sato H, Shimada M, Kurita N, et al. Comparison of long-term prognosis of laparoscopy-assisted gastrectomy and conventional open gastrectomy with special reference to D2 lymph node dissection. Surg Endosc. 2012;26:2240–6.PubMedCrossRef
25.
Zurück zum Zitat Oh SY, Kwon H, Jeong S, et al. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Invest New Drugs. 2012;30:350–6.PubMedCrossRef Oh SY, Kwon H, Jeong S, et al. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Invest New Drugs. 2012;30:350–6.PubMedCrossRef
26.
Zurück zum Zitat Kawaguchi T, Komatsu S, Ichikawa D, et al. Clinical significance of chemotherapy for geriatric patients with advanced or recurrent gastric cancer. Mol Clin Oncol. 2015;3:83–8.PubMedPubMedCentral Kawaguchi T, Komatsu S, Ichikawa D, et al. Clinical significance of chemotherapy for geriatric patients with advanced or recurrent gastric cancer. Mol Clin Oncol. 2015;3:83–8.PubMedPubMedCentral
27.
Zurück zum Zitat Bilici A, Salman T, Oven Ustaalioglu BB, et al. The prognostic value of detecting symptomatic or asymptomatic recurrence in patients with gastric cancer after a curative gastrectomy. J Surg Res. 2013;180:e1–9.PubMedCrossRef Bilici A, Salman T, Oven Ustaalioglu BB, et al. The prognostic value of detecting symptomatic or asymptomatic recurrence in patients with gastric cancer after a curative gastrectomy. J Surg Res. 2013;180:e1–9.PubMedCrossRef
28.
Zurück zum Zitat Renehan AG, Egger M, Saunders MP, O’Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. Br Med J. 2002;324:813.CrossRef Renehan AG, Egger M, Saunders MP, O’Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. Br Med J. 2002;324:813.CrossRef
29.
Zurück zum Zitat Figueredo A, Rumble RB, Maroun J, et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003;3:26.PubMedPubMedCentralCrossRef Figueredo A, Rumble RB, Maroun J, et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003;3:26.PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for nonmetastatic colorectal cancer. Cochrane Database Syst Rev. 2007:CD002200. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for nonmetastatic colorectal cancer. Cochrane Database Syst Rev. 2007:CD002200.
31.
Zurück zum Zitat Tjandra J, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50:1783–99.PubMedCrossRef Tjandra J, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50:1783–99.PubMedCrossRef
Metadaten
Titel
Impact of the Surveillance Interval on the Survival of Patients Who Undergo Curative Surgery for Gastric Cancer
verfasst von
Chan Hyuk Park, MD
Jun Chul Park, MD
Hyunsoo Chung, MD
Sung Kwan Shin, MD
Sang Kil Lee, MD, PhD
Jae-Ho Cheong, MD, PhD
Woo Jin Hyung, MD, PhD
Yong Chan Lee, MD, PhD
Sung Hoon Noh, MD, PhD
Choong Bae Kim, MD, PhD
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2016
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4866-8

Weitere Artikel der Ausgabe 2/2016

Annals of Surgical Oncology 2/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.